Crisugabalin for generalized anxiety disorder
Treatments studied
Part of Mental health clinical trials.
This study tests a new investigational drug called crisugabalin for people with generalized anxiety disorder (GAD) who have not found enough relief from at least two other anxiety medications. The trial aims to see if crisugabalin can safely reduce anxiety symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have a diagnosis of generalized anxiety disorder (GAD) confirmed by a doctor.
- Your anxiety is severe enough that you need medication treatment, and you have not had a good response to at least two prior anxiety medications.
- You do not currently have serious thoughts of suicide, and you have no other active mental health conditions like depression, bipolar disorder, or OCD.
- You do not have serious physical health problems (like heart, liver, or kidney disease) or a history of seizures or drug abuse that could interfere with the study medication.
- You are not pregnant, breastfeeding, or planning pregnancy during the study, and you agree to use reliable birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication called buagafuran for people with generalized anxiety disorder (GAD). It aims to see if the drug can safely reduce anxiety symptoms.
This trial tests a new capsule called Buagafuran for adults with generalized anxiety disorder (GAD). It aims to see if the medication helps reduce anxiety without causing major side effects.
This trial tests an investigational medication to see if it can reduce anxiety symptoms in adults with generalized anxiety disorder. Participants will receive the study drug and be monitored for safety and effectiveness.
This study tests an investigational oral medication (ITI-1284) for people with moderate to severe generalized anxiety disorder (GAD) who haven't found enough relief from at least two standard medications. The goal is to see if this new drug helps reduce anxiety symptoms.
This study tests a new medicine (SEP-363856) for adults with generalized anxiety disorder to see if it reduces anxiety symptoms and is safe. It may help if other treatments haven't worked well.
This trial tests whether an already-studied medication, SEP-363856, can continue to safely help adults with generalized anxiety disorder over a longer period. It may offer ongoing symptom relief for people who completed a previous study of this drug.
Hear when a new Generalized Anxiety Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.